Let's get to it because this is a story you'll want to sink your teeth into.

SmallCapFirm

(NMTC) Is A Nasdaq Low Float Breakout Idea With Massive August News And Bullish Technicals

August 7th

SCF Readers,

Let's get to it because this is a story you'll want to sink your teeth into.

But first an update...

AVCO was brought to your attention after it closed Wednesday's session at $.645.

When Thursday's session came around, it went on an absolute tear running to a 4+ month high of $.8050.

With that run, AVCO became my latest short term stud running approximately 24% in the blink of an eye.

Seeing how hot that healthcare profile came out, I decided to stick to the same industry for this new breakout idea.

Let me ask, what do you know about the future $13.6Bn neurostimulation devices market?

If it's not much, don't worry. All you need to soak in is the sheer size of this potential market by 2027 and let me fill in the details.

I've uncovered a company that is forwarding their game-changing tech to become an industry disruptor, but for now has flown well under Wall Street's radar.

With bullish technical indicators, an explosive chart history, huge August news, and a low float, it may be no better time than now to get this Nasdaq profile on your screen as it recently pushed above now key support lines including its:

  • 50-Day Simple Moving Average (SMA)
  • 13-Day Exponential Moving Average (EMA)

And if potential resistance breaks down at the 200-Day SMA level, which this profile has been battling mightily, all bets could be off on the vertical chart march this breakout idea could make.

Ready for the goods? Here it is:

*NeuroOne Medical Technologies Corporation (NMTC)*

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs.

And right now, NMTC has 5 potential driver indicators to immerse yourself in:

No. 1 - Low Float Volatility Could Grab Hold

No. 2 - Accelerated Milestone Payment Accomplishes Multiple Objectives (Huge News)

No. 3 - Triggered Technicals Could Signal A Near Term Vertical Chart Move

No. 4 - Another Game-Changing Milestone With First Evo sEEG Electrode Clinical Case

No. 5 - A Chart History Of Explosive Short Term Runs

But more on those in a second...

Brain Monitoring - Understanding What Allows Us To Sense, Move, Think And Feel. (1)

Neurons

86 BILLION NEURONS

Neurons communicate through electrical and chemical signals. The specific properties of the neurons composing a brain area and their connections with neurons in other brain areas, define the function of a brain area (e.g. language, vision, movement).

Monitoring Neural Activity

THEY CAN RECORD ELECTRICAL SIGNALS

There are different ways to record and monitor neural activity. Their solution is to provide electrodes that are placed on top of or within the brain and capture the activity of a group of neurons located underneath/around each contact. The signals recorded are called intracranial electroencephalogram (iEEG) or electrocorticography (ECoG) signals. The shape, amplitude and frequency of these electrical signals provide a readout of the activity of that brain area.

Monitoring Neurological Disorders

Neurological diseases may be associated with disturbances in neural activity and connectivity between brain areas. The changes in the shape, amplitude and frequency of recorded electrical signals may be used to identify areas with altered activity.

Epilepsy

Epilepsy is the disease associated with spontaneously recurring seizures. A seizure is a sudden, uncontrolled electrical disturbance in the brain. It can cause changes in behavior, movements or feelings, and in levels of consciousness. There are different types of seizures and their characterization and classification helps guide the treatment.

There are more than twenty seven FDA-approved drugs for the treatment of seizures. However, in ~1/3 of the patient's medication fails to control their seizures. These patients are candidates for surgical options.

Evo® Cortical Electrode

Cortical or subdural electrodes are used in electrocorticography (ECoG) or intracranial electroencephalography (iEEG) surgeries to monitor, record and stimulate the surface of the brain for up to 30 days. The company's Evo cortical electrode portfolio consists of various contact configurations of strip and grid electrodes. (Rx only)

image

The Evo Advantage (2)

Decreased Immunological Response - The Evo Electrode is over 7 times thinner than a silicone electrode. The flexibility and reduced volume should reduce pain and edema.

The Evo’s polyimide substrate has properties like increased flexibility, reduced volume, and decreased immunological response, which should reduce signal artifacts.

Single Tail Design - The single thin tail design allows the implanted electrode tail to be tunneled through one incision which should reduce infection risk and procedure time.

Reduced Cable Management - A disposable cable assembly is sent with each Evo Electrode as an electrode kit, removing the need to source the correct cables for each electrode being used in surgery. Also, hospital resources are freed from the management of sterilizing and storing individual electrode cable assemblies.

image

How NeuroOne's Thin Film Electrode Technology is Different

In comparison to currently available technologies, our electrodes are manufactured with polyimide thin film. Our electrodes are designed to reduce trauma to the brain by allowing a less invasive implant due to the flexibility, thinness and reduced weight of the electrode.

Furthermore, the potential to significantly increase the resolution of brain recordings may enable the usage of powerful computing techniques, such as machine learning and artificial intelligence.

Caution: US Federal law restricts this device to sell by or on the order of a physician

Two FDA-Cleared Devices and Counting (3)

Are you beginning to understand that NeuroOne is not just “another” MedTech company? In fact, their Evo Cortical and sEEG Electrodes are both FDA approved!

What they are doing right now has incredible implications for the future of the medical industry.

So much so that the technologies below could be commonplace and in wide use across the globe.

image

Read more from the company website here.

And as I mentioned previously, NMTC has 5 must-see potential driver indicators right now:

No. 1 NMTC Potential Driver Indicator - Low Float Volatility Could Grab Hold

According to the Yahoo Finance website, NMTC has a low float.

The website reports this profile to have approximately 12.27Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.

-----

No. 2 NMTC Potential Driver Indicator - Accelerated Milestone Payment Accomplishes Multiple Objectives (Huge News)

NeuroOne® Announces $3.5Mn Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode

Amendment provides Zimmer Biomet with 350k warrants with exercise price of $3.00 per share

EDEN PRAIRIE, Minn., Aug. 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc. ("Zimmer") that will provide the Company with a $3.5Mn accelerated payment within 10 business days which relates to certain milestone payments. In addition, Zimmer Biomet will receive a Warrant to purchase 350k shares of the Company's common st-ock, with an exercise price of $3.00 per share.

Dave Rosa, Chief Executive Officer of NeuroOne, states, "I want to thank Zimmer for all their support to date and their confidence in our business, technology and future endeavors. This agreement accomplishes multiple objectives for NeuroOne, most importantly by providing additional capital to our balance sheet in the short-term without the need for a highly dilutive financing, and further reinforcing our ongoing partnership with Zimmer."

Brian Hatcher, President of the Trauma, CMFT, Foot and Ankle Division of Zimmer said, "We look forward to continuing the relationship with NeuroOne as we advance our mission to alleviate pain and improve the quality of life for people around the world." Under the Exclusive Development and Distribution Agreement signed by both parties in July 2020, Zimmer Biomet has exclusive global distribution rights to distribute the Company's Cortical and sEEG diagnostic electrode technology.

Read the full article here.

-----

No. 3 NMTC Potential Driver Indicator - Triggered Technicals Could Signal A Near Term Vertical Chart Move

I'm telling you right now... Don't discount NMTC's technical indicator.

Right now, NMTC has several bullish technical indicators across the short, medium, and long term.

Barchart is reporting these technical indicators as triggered (at close Friday):

Short Term Indicators

  • 20 Day Moving Average
  • 20 - 50 Day MACD Oscillator
  • 20 - 100 Day MACD Oscillator

Medium Term Indicators

  • 50 Day Moving Average

Long Term Indicators

  • 100 Day Moving Average
  • 150 Day Moving Average
  • 200 Day Moving Average

On top of that, Barchart is signaling that its composite "TrendSpotter" indicator is triggered too.

Could this be a signal that things are starting to heat up?

-----

No. 4 NMTC Potential Driver Indicator - Another Game-Changing Milestone With First Evo sEEG Electrode Clinical Case

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode

Case performed at Emory University for intraoperative brain mapping

EDEN PRAIRIE, Minn., July 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo sEEG electrode was performed by Dr. Robert Gross at Emory University. Dr. Gross selected the Evo sEEG electrode for intraoperative brain mapping at the subsurface level of the brain.

Dave Rosa, Chief Executive Officer of NeuroOne, states, "This first clinical case use represents a major milestone achievement of one of our primary objectives for the Company. We are grateful to Dr. Gross and his staff and were excited to hear of the positive experience he had using the electrode. We look forward to continuing to gain clinical experience with the electrode as we prepare to submit a special 510(k) to FDA in August for clearance to commercialize the product for less than 30 days use."

In September 2021, the Company received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG electrode technology for temporary (less than 24 hours) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

The Evo sEEG electrode represents the Company's second FDA 510(k) cleared product, providing a full line of electrode technology to address an estimated worldwide market of $100M for patients requiring diagnostic brain mapping procedures. In comparison with cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a much less invasive process that does not require removal of the top portion of the patient's skull. sEEG has become the predominant technology used in these procedures due to its less invasive placement and subsurface location.

Read the full article here.

-----

No. 5 NMTC Potential Driver Indicator - A Chart History Of Explosive Short Term Runs

Over the past year, NMTC has displayed the ability to make strong intraday/short term moves on multiple occasions.

Just take a look at its chart yourself:

image

Here's a few examples to soak in:

#1. From a low of $3.2581 on 9/1/21, NMTC surged to a high of $6.80 on 9/7/21 for a huge breakout of 108%.

#2. From a $1.70 low on 1/31/22, NMTC once again went running to a high of $3.18 on 2/11/22 for a move of 87%.

#3. More recently, NMTC leaped from a low of $1.1703 on 8/2/22 to a high of $1.95 on 8/3/22 for a blast of 66%.

Like I said, explosive.

-----

NMTC Recap: 5 Potential Breakout Catalysts To Know Immediately

No. 1 - Low Float Volatility Could Grab Hold

No. 2 - Accelerated Milestone Payment Accomplishes Multiple Objectives (Huge News)

No. 3 - Triggered Technicals Could Signal A Near Term Vertical Chart Move

No. 4 - Another Game-Changing Milestone With First Evo sEEG Electrode Clinical Case

No. 5 - A Chart History Of Explosive Short Term Runs

-----

Coverage is officially initiated on NMTC. When time permits, do this:

image

Get NMTC on your radar now.

Sincerely,

Axel Adams

Editor, SCF


Source 1
Source 2
Source 3


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company (SWN Media LLC has recently retained ownership of StockNewsWire LLC). An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaqwirenews . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 8/7/22 and ending on 8/9/22 to publicly disseminate information about (NMTC) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (NMTC). Pursuant to an agreement between SWN Media LLC and Legends Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 8/3/22 and ending on 8/4/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). To date we have been compensated a total of thirty-five thousand USD via bank wire transfer to disseminate information about (AVCO).